CDK9-IN-44

CDK9-IN-44 (Compound 7) is a selective inhibitor of CDK9 with an IC50 of 7.6 μM. It effectively inhibits CDK9/cyclin T1 kinase activity, impedes transcription elongation, reduces the expression of oncogenic proteins such as MCL1 and c-MYC, and induces apoptosis in tumor cells. CDK9-IN-44 shows potential for research in glioblastoma (GBM) and central nervous system (CNS) diseases.